KELIM score: A marker of chemosensitivity in ovarian cancer
Ovarian cancer is the gynecological cancer with the worst prognosis and the highest mortality rate, primarily because 75% of patients are diagnosed with advanced FIGO stage III-IV disease. About 50% of patients are now treated with neoadjuvant chemotherapy followed by interval debulking surgery. In that context, there is a need for accurate predictors of tumor primary chemosensitivity, as it may impact the feasibility of subsequent interval debulking surgery. The cancer antigen 125 ELIMination rate constant K (KELIM) score, a modeled kinetic parameter, is a potential marker of tumor chemosensitivity in patients with ovarian cancer treated with adjuvant or neoadjuvant chemotherapy before interval debulking surgery. This review aims to provide a comprehensive overview of potential predictive factors for response to platinum therapy, focusing on the KELIM score, a marker increasingly used in clinical practice.